Trial Profile
A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 21 Nov 2022 Status changed from active, no longer recruiting to completed.
- 25 May 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.
- 25 May 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2023.